Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus DORYX MPC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus DORYX MPC.
ACTICLATE CAP vs DORYX MPC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Doxycycline, a tetracycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the mRNA-ribosome complex.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
100 mg orally twice daily on day 1, then 100 mg once daily; alternatively, 200 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 25–30 hours) or with hepatic dysfunction.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal (approximately 40% as unchanged drug via glomerular filtration), fecal/biliary (up to 30% as conjugated or inactive metabolites), remainder metabolized.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic